Cour Pharmaceuticals Development

COUR Pharmaceuticals Development Co., Inc. (COUR Pharma) is a privately held, clinical-stage biotechnology company founded in 2012 and headquartered in the Chicago area (Northbrook/Skokie, Illinois), spun out of research at Northwestern University. COUR develops antigen-specific immune tolerance therapies built on its proprietary COUR Nanoparticle (CNP) platform: biodegradable polymer nanoparticles of roughly 500 nm carrying about 1% disease-specific antigen, which mimic apoptotic bodies so that antigen-presenting cells in the liver and spleen re-recognize the antigen as self, deleting pathogenic T cells and expanding regulatory T cells. Active clinical programs include CNP-103 for Type 1 Diabetes and CNP-106 for Myasthenia Gravis, with earlier work in Primary Biliary Cholangitis and Celiac Disease. COUR is a therapeutics developer, not a software or platform company: it publishes no developer program, no public API, and no machine-readable API contract of any kind.

Cour Pharmaceuticals Development is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Immunology.

Cour Pharmaceuticals Development’s developer surface includes engineering blog and 10 more developer resources.

🌐 Visit website 📡 Source on GitHub
10.8/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-08-17 · rubric v0.11.0
0 APIs
CompanyBiotechnologyPharmaceuticalsLife SciencesImmunologyAutoimmune DiseaseClinical TrialsNanotechnologyDrug DevelopmentHealthcare

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-08-17 · rubric v0.11.0
Composite quality — 10.8/100 · minimal
Contract Quality 0.0 / 21
Developer Ergonomics 0.4 / 17
Commercial Clarity 3.6 / 17
Operational Transparency 0.0 / 11
Governance 0.0 / 10
Discoverability 4.3 / 9
Regulatory Posture 2.6 / 15
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 10
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
A2A Agent Card 0 / 8
Dry-Run / Simulate Mode 0 / 4
Regulatory Posture applies to this provider. Its tags matched the Health regime, so Regulatory Posture carries 15 points of the composite. If this regime is wrong for your business, say so on your provider repo — the applicability map is public and we will correct it.
The six quality facets above are damped to 85 points between them, because the conditional facet above carries the other 15. That is why each facet's contribution is shown against a damped maximum: raising a quality facet moves the composite by 85% of its nominal weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/cour-pharmaceuticals-development: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Cour Pharmaceuticals Development Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Commercial 2

Pricing, plans, and the legal terms of use

PrivacyPolicy
PrivacyPolicy
 TermsOfService
TermsOfService

Company 6

The organization behind the API

Website
Website
 About
About
 Blog
Blog
 BlogRSS
BlogRSS
 Partners
Partners
 Careers
Careers

Other 2

Properties that don't map to a standard resource type

Accessibility
Accessibility
 SecondaryMarket
SecondaryMarket

Source (apis.yml)

apis.yml Raw ↑ 
aid: cour-pharmaceuticals-development
name: Cour Pharmaceuticals Development
description: 'COUR Pharmaceuticals Development Co., Inc. (COUR Pharma) is a privately held, clinical-stage biotechnology company
  founded in 2012 and headquartered in the Chicago area (Northbrook/Skokie, Illinois), spun out of research at Northwestern
  University. COUR develops antigen-specific immune tolerance therapies built on its proprietary COUR Nanoparticle (CNP) platform:
  biodegradable polymer nanoparticles of roughly 500 nm carrying about 1% disease-specific antigen, which mimic apoptotic
  bodies so that antigen-presenting cells in the liver and spleen re-recognize the antigen as self, deleting pathogenic T
  cells and expanding regulatory T cells. Active clinical programs include CNP-103 for Type 1 Diabetes and CNP-106 for Myasthenia
  Gravis, with earlier work in Primary Biliary Cholangitis and Celiac Disease. COUR is a therapeutics developer, not a software
  or platform company: it publishes no developer program, no public API, and no machine-readable API contract of any kind.'
url: https://raw.githubusercontent.com/api-evangelist/cour-pharmaceuticals-development/refs/heads/main/apis.yml
image: https://courpharma.com/wp-content/uploads/2025/06/Cour-OG.png
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.20'
created: '2026-08-11'
modified: '2026-08-11'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Immunology
- Autoimmune Disease
- Clinical Trials
- Nanotechnology
- Drug Development
- Healthcare
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/cour-pharmaceuticals-development-domain-security.yml
- type: Website
  url: https://courpharma.com/
- type: About
  url: https://courpharma.com/about-us/
- type: Blog
  url: https://courpharma.com/news/
- type: BlogRSS
  url: https://courpharma.com/feed/
- type: Partners
  url: https://courpharma.com/partnerships/
- type: Careers
  url: https://courpharma.com/careers/
- type: PrivacyPolicy
  url: https://courpharma.com/privacy-policy/
- type: TermsOfService
  url: https://courpharma.com/terms-of-use/
- type: Accessibility
  url: https://courpharma.com/accessibility/
- type: SecondaryMarket
  url: https://forgeglobal.com/cour-pharmaceuticals-development_stock/
x-enrichment:
  date: '2026-08-11'
  status: minimal
  artifacts_added: 2
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: COUR Pharma is a clinical-stage biotech developing CNP nanoparticle immune-tolerance therapies; its entire public
    site is a WordPress marketing/investor site with no developer section, api./developer./docs.courpharma.com do not resolve
    in DNS, and every contract and /.well-known/ probe returned the site's HTML 404 — the only machine-readable endpoint on
    the host is stock WordPress /wp-json/ CMS plumbing (Elementor, Astra, Forminator), not a product API.
  evidence:
  - url: https://courpharma.com/openapi.json
    status: 404
  - url: https://courpharma.com/.well-known/agent-card.json
    status: 404
  - url: https://courpharma.com/.well-known/security.txt
    status: 404
  - url: https://courpharma.com/llms.txt
    status: 404
  - url: https://courpharma.com/graphql
    status: 404
  - url: https://api.courpharma.com/
    status: 0
  checked: '2026-08-11'